問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

陳彥豪
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

264Cases

2016-12-15 - 2020-06-08

Phase III

Not yet recruiting
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Asian Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
  • Condition/Disease

    Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Keytruda

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2018-10-17 - 2024-08-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-03-01 - 2028-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-01-20 - 2025-08-15

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

2026-02-26 - 2028-04-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2024-11-01 - 2027-04-30

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-05-02 - 2023-04-18

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-03-01 - 2024-12-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-10-01 - 2022-08-24

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-05-31 - 2026-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites